Latest news with #Ivana
GMA Network
3 days ago
- Entertainment
- GMA Network
Ivana Alawi, Charlie Fleming prank Kira Balinger, AC Bonifacio, Ashley Ortega in new vlog
Ashley Ortega, AC Bonifacio, and Kira Balinger just got pranked by Ivana Alawi and Charlie Fleming! On YouTube, Ivana shared a 24-minute vlog which featured Charlie and former "Pinoy Big Brother: Celebrity Collab Edition" housemates AC, Ashley, and Kira. The video began with the five girls feasting over king crabs and talking about their fondest memories inside Bahay ni Kuya. When they talked about their first impressions, Ivana said she thought Charlie was 23, even though she was actually just 16. "You are matured for your age na parang if I didn't ask your age, iisipin ko talagang matanda ka. Ang matured niya mag-isip, tapos minsan parang sumosobra talaga. Sometimes she needs to control. Ngayon makikita mo, mabait naman siya," Ivana said of Charlie. Upon hearing Ivana's confession, Charlie said: "Ate parang binabalikan mo ata 'yon eh?" referring to their past rift inside the house where Ivana called her out because of her attitude. In response, Ivana reprimanded Charlie for her attitude as well as for coming late to their supposed 11 a.m. call time for the vlog. "Ngayon lang kami nagkita-kita. I mean, 'di ba dapat OK tayong lahat?" Ivana asked. "OK naman eh. Parang binabalikan mo lang," Charlie answered back which baffled Ivana. As the things escalated between the two, Ivana walked out and Charlie turned emotional which prompted Kira, Ashley and AC to settle things out. Ashley and Kira went to comfort Ivana with the former asking "Prank ba 'to?" "Hindi ako magpa-prank ng ganyang ugali. First time lang namin magkita. Atsaka hindi ako nagpa-prank ng hindi nakaka-inspire," Ivana answered. AC then spoke to Charlie, advising her to simply apologize to Ivana. Ivana approached Charlie and asked her what her problem was. "Mag-so-sorry na nga sana ako sa 'yo eh!" Charlie answered. Ivana said, "Eh bakit ka ganyan magsalita?" Feeling the heaviness of the situation, Kira, AC and Ashley sat down with Ivana and Charlie to talk things out. As Ivana and Charlie settled their argument, Ivana suddenly blurted out, "It's a prank!" Charlie burst into laughter, leaving the three girls stunned. "Sabi ko na nga ba eh. Sinabi ko na sa 'yo eh," Ashley said. "Hindi ganyan si Charlie eh. Hindi ganyan eh. Sabi ko, 'ang OA ni Charlie sumagot ngayon.' Hindi siya ganon," AC added. Shortly after the prank, a flashback clip showed Ivana calling Charlie and talking about the plan to prank Kira, AC, and Ashley. AC-Ashley and Charlie-Kira were the first two duos evicted from "Pinoy Big Brother: Celebrity Collab Edition." Meanwhile, Ivana was among the house guests who briefly stayed inside Bahay ni Kuya. She pretended to be a housemate at first and was paired with Ashley as her "duo." The five then reunited and took a photo together before Charlie returned to Bahay ni Kuya after winning a wildcard slot. —Jade Veronique Yap/MGP, GMA Integrated News
Yahoo
21-05-2025
- Business
- Yahoo
Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi
- Vigil's shareholders to receive up to $10.00 per share in cash, comprised of $8.00 per share in cash at closing and a non-tradeable contingent value right of $2.00 per share in cash following the first commercial sale of VG-3927 - - Acquisition expected to strengthen development path for the oral small molecule TREM2 agonist program, including VG-3927, a Phase 2-ready clinical candidate for potential treatment of Alzheimer's disease – - Companies expect transaction to close in third quarter of 2025 - WATERTOWN, Mass., May 21, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases and Sanofi (NASDAQ: SNY), today announced that it has entered into a definitive merger agreement pursuant to which Sanofi will acquire Vigil for an upfront payment of $8.00 per share of common stock in cash. Vigil shareholders will also receive a non-tradeable contingent value right (CVR) entitling the holder to potentially receive an additional $2.00 per share in cash payable following the first commercial sale of VG-3927 if achieved within a specific period. The total equity value of the transaction, including the potential CVR payment, represents approximately $600 million on a fully diluted basis. "We are incredibly proud of the legacy we have built at Vigil and today's announcement is a testament to the value of our TREM2 agonist pipeline,' said Ivana Magovčević-Liebisch, Ph.D., J.D., President and Chief Executive Officer of Vigil. 'Sanofi's development capabilities, therapeutic expertise, global footprint, and financial strength provide the greatest opportunity to further the development of VG-3927 for the potential treatment of Alzheimer's disease and potentially bring this important and differentiated therapy to those struggling with the immense burden of this disease.' Activating TREM2 is expected to enhance the neuroprotective function of microglia in Alzheimer's disease. In neurodegenerative diseases such as Alzheimer's disease, microglial activation is dysregulated, leading to debris accumulation, chronic inflammation and neurodegeneration in the central nervous system. Activation of TREM2 has shown to promote the migration of microglial cells to sites of injury, enhance their capability for phagocytosis, proliferation, and survival. Consequently, this facilitates the prevention of neural degeneration that is frequently associated with adult-onset neurodegenerative diseases. Currently approved therapies for Alzheimer's disease do not stop or reverse the disease progression and there are stringent eligibility requirements for treatment. There is a critical need to develop more efficacious, safer, and convenient options for people living with Alzheimer's disease. 'Sanofi's complementary capabilities and commitment to bring innovative therapies to patients align with our mission and what we have passionately been working toward over the past five years,' continued Magovčević-Liebisch. 'We want to thank Vigil's exceptional employees for their unrelenting dedication and our patient communities for their steadfast engagement, to whom I extend my deepest gratitude. Together, we look forward to following Sanofi's journey in advancing next-generation small molecule TREM2 therapies for severe neurodegenerative diseases and potentially offering new treatment options to patients.' 'This acquisition is fully supporting Sanofi's strategic focus on neurology and on advancing science and leveraging our expertise in immunology to solve areas of critical unmet need,' said Houman Ashrafian, M.D., Ph.D., Head of Research and Development of Sanofi. 'TREM2 represents a compelling target at the intersection of immune dysregulation and neurodegeneration, particularly in people living with Alzheimer's because they face devastating cognitive decline with limited treatment options. Vigil's expertise is complementary to our capabilities in neurology and reinforces our dedication to developing innovative medicines to improve people's lives. Vigil's team are a welcome addition, and we look forward to working with them and the patient community.' Terms of the Transaction Under the terms of the merger agreement, Sanofi and Vigil have agreed to the following: Sanofi will acquire all outstanding common shares of Vigil for $8.00 per share in cash at closing, representing an equity value of approximately $470 million (on a fully diluted basis) In addition, Vigil's shareholders will receive a non-transferrable CVR per Vigil share, which will entitle its holder to receive a deferred cash payment of $2.00, conditioned upon the first commercial sale for VG-3927. Iluzanebart (VGL101), Vigil's monoclonal antibody program, is not being acquired by Sanofi, and its return to Amgen, the original licensor, and the termination of the exclusive license agreement with Amgen solely with respect to VGL101, will occur prior to the closing of the transaction. Bruce Booth, Atlas Ventures, and Ivana Magovčević-Liebisch have signed voting and support agreements in favor of the deal. The shares subject to these agreements represent a total of approximately 16% of Vigil's total common shares outstanding. The closing of the acquisition is subject to other conditions customary for such a transaction, including the approval of holders of a majority of the outstanding shares of Vigil common stock, the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, and other customary conditions. Sanofi and Vigil expect the transaction to close in the third quarter of 2025. AdvisorsCenterview Partners LLC is acting as exclusive financial advisor to Vigil, and Goodwin Procter LLP is serving as legal counsel. About SanofiWe are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY. About Vigil NeuroscienceVigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Vigil is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its efforts to develop precision-based therapies to improve the lives of patients and their families. Iluzanebart, Vigil's lead clinical candidate, is a fully human monoclonal antibody agonist targeting triggering receptor expressed on myeloid cells 2 (TREM2) in people with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. Vigil is also developing VG-3927, a novel small molecule TREM2 agonist, to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease (AD). Forward Looking Statements This communication includes certain disclosures that contain express or implied forward-looking statements related to Sanofi, Vigil and the acquisition of Vigil by Sanofi that are made pursuant to the safe harbor provisions of the federal securities laws, including, without limitation, express or implied forward-looking statements regarding: Vigil's strategy, business plans and focus; the potential therapeutic benefit of the Company's product candidates, including iluzanebart and VG-3927; the return of VGL101 to Amgen (VGL101 Return); the progress and timing of the clinical development of Vigil's product candidates and programs; beliefs about observations made analyzing preclinical study and clinical trial data to date; and the future operations and performance of Sanofi and Vigil. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including all statements regarding the intent, belief or current expectation of the companies and members of their senior management teams. Words such as 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'target,' variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of such forward-looking statements include, but are not limited to, express or implied: statements regarding the transaction and related matters, expected timelines for completing the transaction, prospective performance and opportunities, post-closing operations and the outlook for the companies' businesses; statements of targets, plans, objectives or goals for future operations, including those related to Sanofi's and Vigil's products, potential therapeutic benefit, product research, product development, product introductions and product approvals as well as cooperation in relation thereto; statements containing projections of or targets for revenues, costs, income (or loss), earnings per share, capital expenditures, dividends, capital structure, net financials and other financial measures; statements regarding future economic performance, future actions and outcomes of any potential future legal proceedings; and statements regarding the assumptions underlying or relating to such statements. These statements are based on current beliefs, judgments and assumptions based upon information currently available to Sanofi and Vigil management and utilized to develop plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. Sanofi and Vigil each caution that a number of important factors, including those described in this document, could cause actual results to differ materially from those contemplated in any forward-looking statements. Factors that may affect future results and may cause these forward-looking statements to be inaccurate include, but are not limited to: the occurrence of any event, change or other circumstance that could give rise to the termination of the transaction; the possibility that competing offers will be made; the possibility that various closing conditions for the transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction (or only grant approval subject to adverse conditions or limitations) or the receipt of the requisite approval of Vigil's stockholders; the possibility that the proposed transaction may not be completed in the time frame expected by Sanofi and Vigil, or at all; the possibility that the VGL101 Return may not be completed in the anticipated time frame or at all; failure to realize the anticipated benefits of the proposed transaction in the time frame expected, or at all; the effects of the transaction on relationships with employees, other business partners or governmental entities; potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed transaction; significant or unexpected costs, charges or expenses resulting from the proposed transaction; negative effects of this announcement or the consummation of the proposed transaction on the market price of Sanofi's shares or Vigil's common stock and/or Sanofi's or Vigil's operating results; potential difficulties in employee retention as a result of the announcement and pendency of the proposed transaction; the difficulty of predicting the timing or outcome of regulatory approvals or actions; the risks related to non-achievement of the CVR milestone and that holders of the CVRs will not receive payments in respect of the CVRs; other business effects, including the effects of industry, economic or political conditions outside of Vigil's or Sanofi's control; potentially significant political, trade or regulatory developments and other circumstances beyond Vigil's control, including government shutdowns, layoffs, voluntary resignations and reorganizations, new legislation and executive orders, trade disputes and tariffs; transaction costs; actual or contingent liabilities; risk of litigation and/or regulatory actions related to the proposed transaction; the outcome of any legal proceedings that may be instituted against the parties and others related to the proposed transaction; adverse impacts on business, operating results or financial condition in the future due to pandemics, epidemics or outbreaks and their impact on Sanofi's and Vigil's respective businesses, operations, supply chain, patient enrollment and retention, clinical trials, strategy, goals and anticipated milestone; government-mandated or market-driven price decreases for Sanofi's or Vigil's products; introduction of competing products; reliance on information technology; Sanofi's or Vigil's ability to successfully market current and new products; Sanofi's, Vigil's and their collaborators' ability to continue to conduct research and clinical programs; Vigil's ability to successfully demonstrate the efficacy and safety of its product candidates, the therapeutic potential of its product candidates and the preclinical or clinical results for its product candidates, which may not support further development of such product candidates; comments, feedback and actions of regulatory agencies; exposure to product liability and legal proceedings and investigations; and other risks and uncertainties detailed from time to time in Vigil's periodic reports filed with the U.S. Securities and Exchange Commission (SEC) and Vigil's other filings with the SEC. Any forward-looking statements speak only as of the date of this communication and are made based on the current beliefs, judgments and assumptions based upon information currently available to Sanofi's and Vigil's management. Forward-looking statements contained in this announcement are made as of this date, and Sanofi and Vigil undertake no duty to update such information except as required under applicable law. Readers should not rely upon the information on this page as current or accurate after its publication date. Additional Information And Where To Find It In connection with the proposed transaction between Vigil and Sanofi, Vigil will file with the SEC a proxy statement on Schedule 14A (Proxy Statement) relating to a special meeting of its stockholders. Additionally, Vigil may file other relevant materials with the SEC in connection with the proposed transaction. VIGIL'S STOCKHOLDERS AND OTHER INVESTORS ARE URGED TO READ THE PROXY STATEMENT AND ANY OTHER RELEVANT MATERIALS FILED OR THAT WILL BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE MATERIALS AND DOCUMENTS INCORPORATED BY REFERENCE THEREIN, CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND RELATED MATTERS. The definitive Proxy Statement will be mailed or otherwise made available to Vigil's securityholders. Investors and securityholders will be able to obtain a copy of the Proxy Statement as well as other filings containing information about the proposed transaction that are filed by Vigil or Sanofi with the SEC, free of charge on EDGAR at Participants in the SolicitationVigil and certain of its directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Vigil in respect of the proposed transaction and any other matters to be voted on at the special meeting. Information about Vigil's directors and executive officers, including a description of their interests, by security holdings or otherwise, in the proposed transaction will be included in the Proxy Statement. Vigil stockholders may obtain additional information regarding the participants in the solicitation of proxies in connection with the proposed transaction by reading the Proxy Statement and any other relevant documents that are filed or will be filed with the SEC relating to the proposed transaction. You may obtain free copies of these document using the sources indicated above. Internet Posting of InformationVigil routinely posts information that may be important to investors in the 'Investors' section of its website at The Company encourages investors and potential investors to consult our website regularly for important information about Vigil. Investor Contact:Leah GibsonVice President, Investor Relations & Corporate CommunicationsVigil Neuroscience, Media Contact:Megan McGrathCTD Comms, LLCmegan@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
New York Post
14-05-2025
- Business
- New York Post
Hochul jokes congestion pricing might not work— after NYC traffic made her late for dinner
They're hitting the city limits Out of the mouths: Kathy Hochul — always on the dot punctual, and meeting a friend for dinner — arrived 20 minutes late. 'Traffic was terrible,' she said. Then: 'Maybe this congestion thing isn't working!' For over 40 years the owner of big-time restaurant Primola has served everyone — Ivana, Ivanka, Marla, Donald 'who always came a few minutes late.' East Side owner says, 'If ever I actually write a book, I'd have to leave the country.' Realtor: High cost of everything causing problems, union carpenters, congestion and bridge tolls, 'besides that there's also kids, 12 years old, in Times Square robbing people.' Taxi driver: 'When passengers pay in cash I now don't have to report it.' Driven to drink Wait. More taxi driver misery. Marilu Henner and Tony Danza couldn't find a taxi. They were damp. It was the rained-on West Wide. Ubers were backed up. Cabs no place. Understand, these were the former TV 'Taxi' stars. So, in good Big Apple style, they sloshed over for drinks at dry Manny's Bistro. Big cheers for Jersey boy Lufthansa lounge before a flight to Copenhagen. Newark Airport. TSA staff snarling. Hasidim speaking Yiddish. Passengers said that this week downtown Tenafly had 10 million Israeli-Americans and assorted persons of Jewish persuasion celebrating 21-year-old Edan Alexander's release from hostagehood. High value asset We now speak bargains. You can go from bland to Bond for $26.5 mil. Sean Connery's South of France shack is for sale. Stuck above the Mediterranean in Nice. Art Deco estate called 'Bond Villa' by locals. Riviera glamour, panoramic sea views, indoor infinity pool, dining room equipped with ejector seats for gabby guests in case the pot roast's lousy. Rule of all? Europe is at a critical point. America's shield is rusting. China's prepping to invade Taiwan. Took only one month, three weeks, two days to bring down the Weimar Republic and its constitution. Putin's goal? A redo of Yalta, where half the continent was ceded to Stalin. The south awaits the current conflict outcome to decide whether or not to act further — whether to trample on it. He wants the order put in place by the USA and its allies. First principle being the prohibition of acquiring territory by force. E pluribus unum. Somewhere I read that it's all for one — and one for all. Only not in New York or anyplace else.
Scottish Sun
14-05-2025
- Lifestyle
- Scottish Sun
The 7 expert hacks to help your garden feel bigger this summer from the colours you use to the size of your furniture
Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) AN expert has revealed seven tricks to make your garden feel bigger this summer, from colours to the size of your furniture. With the sun blazing down on the UK this week, many of us are likely spending as much time as possible in the garden. Sign up for Scottish Sun newsletter Sign up 3 An expert has shared seven tips to make your garden look bigger Credit: Getty However, if you've noticed that your outdoor space is looking a little cramped, you may be wondering if there's anything you can do to make it look bigger. With this is mind, Ivana Agustina, Head of Project Management at ShrubHub, an award-winning online landscape design service has revealed seven things to do to make your tiny outside area look like a sprawling haven. Create Zones The expert revealed that breaking your garden up into different zones makes it feel larger than if it is just a single open area. 'The human brain perceives multiple small experiences as more substantial than one uniform space,' Ivana explained. Read more garden stories FEELING FRESH Lidl is selling a £9 garden gadget to keep lawn green and healthy this summer 'By dividing your garden into zones – perhaps a dining area, a lounge space, and a planting section – visitors mentally 'travel' through your garden, making it feel much bigger.' Diagonal Lines Ivana explained that breaking your garden up into diagonal lines tricks your eyes into thinking that the space is bigger than it actually is. 'Garden pathways or patio pavers laid at a 45-degree angle create an illusion of expansion," she said. 'This works particularly well in rectangular gardens, where the diagonal lines fight against the boxy boundaries.' Vertical Gardens If you have limited space in your garden, growing plants up trellises or on walls can make the garden feel bigger. "Vertical gardening is both practical and visually expanding,' the expert said. I made a DIY fence for £68 with pallets from Facebook Marketplace - it gives more privacy & people say it's 'fantastic' 'By drawing the eye upward with wall-mounted planters, trellises with climbing plants, or tall, narrow planters, you create height that makes the garden feel more spacious.' Strategic Colours Even the different colours you use in your garden can affect how big the space looks, according to the expert. She advised: "Place brighter colours like yellows and oranges near the entrance of your garden, transitioning to cooler blues and purples at the far end." 'Cool colours visually recede, making that section of the garden seem farther away than it actually is.' Garden features that add the most value to a house A well-kept garden can add anywhere between 5-20% to the value of a property. carried out a study and consulted 36 estate agents, garden designers and property professionals from across the UK. And the experts revealed the garden feature which adds the most value to a property is a shed. Shed - 82% Patio or paving - 76% Secure fencing, walls or gates - 72% Outdoor lighting - 66% Sturdy decking - 62% Water features eg. fountain or pond - 58% Modern garden furniture - 54% Artificial lawn/grass - 40% Mirrors Mirrors are often used to make the inside of homes look big, and you can use this trick in the garden too. 'An outdoor-rated mirror placed at the end of a garden reflects plantings and sky, effectively doubling the visual space,' Ivana said. 3 Mirrors can make your garden look bigger Credit: Getty 'For safety, choose shatterproof acrylic mirrors designed for outdoor use.' B&M is currently selling an Al Fresco round sectioned mirror for £10 which will make your garden look huge for a bargain price. Furniture Size Having a huge set of garden furniture in a tiny garden overwhelms the space, make your garden look minuscule. Instead Ivana recommend picking smaller furniture and, to give the area "breathing room." 3 Choose furniture that is an appropriate size for your garden Credit: Getty She added that this trick also applies to greenery, and recommended planting small plants instead of enormous trees. Create Mystery "Human curiosity is a powerful tool in garden design,' Ivana said. 'When we can't see everything at once, we perceive there's more to discover.' The expert recommended partially screening areas with tall grasses, bamboo, or lattice panels that "hint at spaces beyond without fully revealing them".
Time of India
13-05-2025
- Entertainment
- Time of India
Adivi Sesh praises Sree Vishnu's '#Single'; Calls it a laugh riot after watching in packed theatre
Sree Vishnu's Telugu comedy-drama '#Single' is gaining traction, celebrated by Adivi Sesh after viewing it in a packed theater. He lauded the cast's comic timing, particularly Sree Vishnu and Vennela Kishore, alongside Ketika Sharma and Ivana. The film revolves around Vijay's quest for love, navigating humorous romantic entanglements, with speculation of an upcoming OTT release on Amazon Prime Video. Telugu comedy-drama '#Single', starring Sree Vishnu , has steadily gained popularity at the box office since. Recently, actor Adivi Sesh shared his appreciation for the film on social media, revealing that he watched the film in a packed theatre. On his Instagram stories, the actor applauded the comic timing and efforts of the entire cast, especially highlighting Sree Vishnu and Vennela Kishore 's performances, along with the talents of Ketika Sharma and Ivana. On Instagram, he wrote, "Loved watching the comedy from Hero @sreevishnu29 and my darling @vennelakish in a full theater last night! @ketikasharma and #Ivana are so funny n talented as well. Congratulations to the whole team on the success of #Single." by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Trade Bitcoin & Ethereum – No Wallet Needed! IC Markets Start Now Undo The story revolves around Vijay played by Sree Vishnu, a cheerful bank employee tired of his single life. He pursues love with determination, first trying to win over Purva portrayed by Ketika Sharma, only to have his plans complicated by Harini played by Ivana, who also shows interest in him. The film humorously explores Vijay's romantic dilemmas and his quest to find companionship. On social media, viewers have shared positive reactions, appreciating the film's lightheartedness and relatable moments, especially among younger audiences. The presence of veteran comedian Vennela Kishore adds a strong comedic element that many found enjoyable. On X (formerly Twitter) many tweets describe the first half as a laugh riot filled with witty one-liners and nonstop fun, making it a perfect lighthearted entertainer for the summer. While the comedy and performances have been widely appreciated, some viewers pointed out that the second half feels a bit rushed and the emotional scenes lack depth. According to M9News, there are speculations that the film will be released on Amazon Prime Video on OTT after its theatrical release. However, an official announcement is yet to be made.
